​

RedHill Biopharma (RDHL) Stock Forecast, Price Target & Predictions

OverviewOwnershipChart

RDHL Stock Rating

RedHill Biopharma stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 10 Strong Sell Sell Hold Buy Strong Buy

RDHL Price Target Upside V Benchmarks

TypeNameUpside
StockRedHill Biopharma-
SectorHealthcare Stocks 15.45%
IndustrySpecialty & Generic Drug Manufacturers Stocks18.82%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.53$1.53$1.53
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 24-4---4
Oct, 24-4---4
Sep, 24-4---4
Aug, 24-4---4
Jul, 24-1---1
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change

Financial Forecast

EPS Forecast

$-3K $-2K $-1K $-700 $-100 $500 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$-97.75$-98.27$-38.27$3.68---
Avg Forecast$-1.78K$-2.03K$-70.00$-80.00$-40.00$-10.00-
High Forecast$-1.78K$-2.03K$-70.00$-80.00$-40.00$-10.00-
Low Forecast$-1.78K$-2.03K$-70.00$-80.00$-40.00$-10.00-
Surprise %-94.50%-95.17%-45.33%-104.60%---

Revenue Forecast

$5M $22M $39M $56M $73M $90M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$64.36M$85.76M$61.80M$6.51M---
Avg Forecast$68.13M$87.90M$68.00M$9.00M$20.80M$38.00M$50.60M
High Forecast$68.13M$87.90M$68.00M$9.00M$20.80M$38.00M$50.60M
Low Forecast$68.13M$87.90M$68.00M$9.00M$20.80M$38.00M$50.60M
Surprise %-5.54%-2.44%-9.12%-27.63%---

Net Income Forecast

$-15B $-11B $-7B $-3B $1B $5B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$-89.02M$-114.31M$-59.24M$23.85M---
Avg Forecast$-11.52B$-70.20M$-69.50M$-69.22M$-259.12M$-64.78M-
High Forecast$-11.52B$-56.16M$-55.60M$-55.38M$-259.12M$-64.78M-
Low Forecast$-11.52B$-84.24M$-83.39M$-83.07M$-259.12M$-64.78M-
Surprise %-99.23%62.83%-14.75%-134.46%---

RDHL Forecast FAQ

Is RedHill Biopharma stock a buy?

RedHill Biopharma stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that RedHill Biopharma is a favorable investment for most analysts.

What is RedHill Biopharma's price target?

RedHill Biopharma's price target, set by 10 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $1.53.

How does RedHill Biopharma stock forecast compare to its benchmarks?

RedHill Biopharma's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the specialty & generic drug manufacturers stocks industry (18.82%).

What is the breakdown of analyst ratings for RedHill Biopharma over the past three months?

  • November 2024: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2024: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2024: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is RedHill Biopharma’s EPS forecast?

RedHill Biopharma's average annual EPS forecast for its fiscal year ending in December 2024 is $-40, marking a -1186.96% decrease from the reported $3.68 in 2023. Estimates for the following years are $-10 in 2025, and $0 in 2026.

What is RedHill Biopharma’s revenue forecast?

RedHill Biopharma's average annual revenue forecast for its fiscal year ending in December 2024 is $20.8M, reflecting a 219.35% increase from the reported $6.51M in 2023. The forecast for 2025 is $38M, and $50.6M for 2026.

What is RedHill Biopharma’s net income forecast?

RedHill Biopharma's net income forecast for the fiscal year ending in December 2024 stands at $-259M, representing a -1186.27% decrease from the reported $23.85M in 2023. Projections indicate $-64.781M in 2025, and $0 in 2026.